Skip to headlines

BUSINESS

Novo says Wegovy injection lowers BMI and obesity rates in children in trial

CNBC BusinessMonday, November 16, 2026 at 3:00 PM

RedScroll Brief

Wegovy is already approved to treat obesity in children ages 12 and older, but there are currently no approved medications for those under 12.

RedScroll Signal

Impact
High
Category
Business
Market relevance
High
Why it matters
Corporate and market moves reprice risk and reveal where power and cash are concentrating. Wegovy is already approved to treat obesity in children ages 12 and older, but there are currently no approved medications for those under 12. Investors will watch earnings, rates, and competitive positioning connected to Novo and Wegovy.

Desk copy

RedScroll Briefing

Extractive editorial brief — not a reprint of the original

What happened

Wegovy is already approved to treat obesity in children ages 12 and older, but there are currently no approved medications for those under 12.

Why it matters

Corporate and market moves reprice risk and reveal where power and cash are concentrating.

Background

CNBC Business reported on this under business. RedScroll surfaces the signal with an extractive brief — not a reprint of the original article. Read the source for full reporting.

Timeline

  1. CNBC Business published: Novo says Wegovy injection lowers BMI and obesity rates in children in trial

  2. Story is in today’s RedScroll edition. Follow the original source for updates.

Economic impact

Investors will watch earnings, rates, and competitive positioning connected to Novo and Wegovy.

More on

Related stories

Source

CNBC Business

Original reporting by CNBC Business. RedScroll provides an extractive briefing only.